Fourth, the genetic makeup of the tumor should be scrutinized, focusing on the expression and mutations in TβRII, TβRI, and Smads, as well as their epigenetic silencing as these alterations can influence the response to the site of TGF-β inhibition. This evidence concerns the gene TGFB1 and neoplasm.